HER2 in breast cancer in Sohag Governorate
This study looks at breast cancer cases diagnosed in 2025 and 2026 to learn more about a protein called HER2, which can affect how cancer grows. Your participation could help doctors better understand HER2 in breast cancer in this region.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with breast cancer in 2025 or 2026.
- Had a biopsy or surgery to diagnose breast cancer.
- The tissue sample is available for additional testing.
- Your medical records include complete information about your care.
- You are willing to allow researchers to review your tissue sample.
- fitModel.questions.0.include_if_ignore_this_field_that_will_break_strict_additionalProperties_but_here_for_demonstration_only_because_spec_requires_it_to_be_absent_but_we_have_to_obey_schema_which_is_sibling_to_properties_so_we_can't_put_it_here.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at medical records of people with a certain type of esophageal or stomach cancer to see how HER2 status relates to patient outcomes. It may help guide future treatment decisions.
This trial is looking at whether HER2, a protein linked to some cancers, is found in different gynecologic tumors. It tests stored tumor tissue from women in Brazil to learn more about this marker.
This study looks at a test called HER2 IHC (a way to check for a protein called HER2 on tumor cells) in people with certain cancers: non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), gynecological cancers (cervical, endometrial, ovarian), and urothelial cancer (UC). It aims to see how well the test works in different patients. You may join if you have enough stored tumor tissue from a biopsy or surgery done within the past 5 years.
This study is looking at how common HER2 gene changes are in people with advanced non-small cell lung cancer (NSCLC) and how these changes affect treatment. By joining, you help researchers learn more about personalized care for this type of lung cancer.
This study looks at genetic factors to understand why some people’s HER2-positive breast cancer responds better—or has more side effects—after treatment. Your info and possible past treatment history may help researchers improve how HER2 treatment is chosen and managed.
This registry tracks people with HER2-positive breast cancer to learn more about the disease and how it's treated. You can join at any stage of cancer.
Hear when a new HER2 Status in Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.